Here's why the Total Brain (ASX:TTB) share price is rocketing 58% today

The company has announced a data licensing agreement. Here are the details

Child wearing a space helmet and sitting with thumbs up next to two toy rockets on a desk with a computer, keyboard and mouse.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Total Brain Ltd (ASX: TTB) share price is rebounding after hitting an all-time low of 9.4 cents on Friday. This comes after the digital mental health software-as-a-service (SaaS) company announced a data licensing agreement that has excited investors.

At the time of writing, Total Brain shares are surging a whopping 57.89% to 15 cents apiece.

Total Brain secures data licensing agreement

In a statement to the ASX, Total Brain advised it has entered into a perpetual, non-exclusive licence with Janssen Research & Development, LLC.

Founded in 2001, Janssen supports the pharmaceutical business of global healthcare behemoth, Johnson & Johnson.

Janssen specialises in researching, developing, and producing medicines for a range of diseases. This relates to areas such as cardiovascular and metabolism, immunology, infectious diseases and vaccines, neuroscience, oncology, and pulmonary hypertension.

Under the agreement, Janssen will have access to Total Brain's iSPOT-D (International Study to Predict Optimized Treatment for Depression) research data. The licensing deal is effective immediately.

As such, Total Brain will receive a one-off licence fee of US$2.2 million within the next 90 days.

This will indeed boost the company's cash runway significantly for research activities beyond the June 2022 quarter. Previously, Total Brain had $2.6 million at the end of September 2021.

More on Total Brain

Based in San Francisco and Sydney, Total Brain has developed the world's first mental health self-monitoring and self-care platform.

Its SaaS platform has helped more than 1 million users scientifically measure and optimise their brain capacities while managing the risk of common mental conditions.

These benefits for employers, large organisations, and insurers have translated to productivity improvements and healthcare cost reduction.

Total Brain share price snapshot

Over the past 12 months, the Total Brain share price has lost around 52%. It is also down roughly 53% this year to date. It is a stark contrast from when the company's shares reached a 52-week high of 50.5 cents in January 2021.

On valuation grounds, Total Brain presides a market capitalisation of about $17.34 million, with 133.39 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned.

More on Healthcare Shares

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX 200 stock is jumping 10% on big news

This stock is catching the eye with a strong gain on Thursday. But why?

Read more »

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »